You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethylphenobarbital
Accession NumberDB00849  (APRD00047)
TypeSmall Molecule
GroupsApproved
DescriptionA barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital. [PubChem]
Structure
Thumb
Synonyms
1-Methylphenobarbital
5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-1-methyl-5-phenyl-pyrimidine-2,4,6-trione
5-Ethyl-1-methyl-5-phenylbarbituric acid
Enphenemal
Mebaral
Mephobarbital
Mephobarbitone
Méthylphénobarbital
Methylphenobarbital
Methylphenobarbitalum
Methylphenobarbitone
Metilfenobarbital
Metilfenobarbitale
N-Methylphenobarbital
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MebaralLundbeck A/S
MephyltalettenNot Available
PhemitonNot Available
PhemitoneNot Available
PhenmitonNot Available
ProminalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5NC67NU76B
CAS number115-38-8
WeightAverage: 246.2619
Monoisotopic: 246.100442324
Chemical FormulaC13H14N2O3
InChI KeyInChIKey=ALARQZQTBTVLJV-UHFFFAOYSA-N
InChI
InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)
IUPAC Name
5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
SMILES
CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • Benzenoid
  • 1,3-diazinane
  • Monocyclic benzene moiety
  • Urea
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the relief of anxiety, tension, and apprehension, also used as an anticonvulsant for the treatment of epilepsy.
PharmacodynamicsMethylphenobarbital, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
Mechanism of actionMethylphenobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Related Articles
AbsorptionApproximately 50% of an oral dose of mephobarbital is absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding70-76%
Metabolism

Hepatic, primarily by the hepatic microsomal enzyme system. About 75% of a single oral dose of mephobarbital is metabolized to phenobarbital in 24 hours.

SubstrateEnzymesProduct
Methylphenobarbital
Not Available
PhenobarbitalDetails
Route of eliminationNot Available
Half life34 (range 11-67) hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.9859
Caco-2 permeable+0.5674
P-glycoprotein substrateNon-substrate0.6107
P-glycoprotein inhibitor INon-inhibitor0.5213
P-glycoprotein inhibitor IINon-inhibitor0.8987
Renal organic cation transporterNon-inhibitor0.8913
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateNon-substrate0.6613
CYP450 1A2 substrateNon-inhibitor0.857
CYP450 2C9 inhibitorNon-inhibitor0.6815
CYP450 2D6 inhibitorNon-inhibitor0.9404
CYP450 2C19 inhibitorNon-inhibitor0.7403
CYP450 3A4 inhibitorNon-inhibitor0.935
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9254
Ames testNon AMES toxic0.727
CarcinogenicityNon-carcinogens0.754
BiodegradationNot ready biodegradable0.9668
Rat acute toxicity2.6756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9848
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Mentax 1% cream4.0USD g
Mebaral 100 mg tablet1.73USD tablet
Mebaral 50 mg tablet1.28USD tablet
Mebaral 32 mg tablet0.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point176 °CPhysProp
water solubilitySlightly solubleNot Available
logP1.84HANSCH,C ET AL. (1995)
pKa7.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.71 mg/mLALOGPS
logP1.95ALOGPS
logP1.63ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)8.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.48 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity64.64 m3·mol-1ChemAxon
Polarizability24.62 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.57 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN03AA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Methylphenobarbital can be decreased when combined with Abiraterone.
AcebutololMethylphenobarbital may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Methylphenobarbital.
AcepromazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Methylphenobarbital.
AcetazolamideMethylphenobarbital may increase the hypotensive activities of Acetazolamide.
adipiplonThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Agomelatine.
AldesleukinMethylphenobarbital may increase the hypotensive activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methylphenobarbital.
AliskirenMethylphenobarbital may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methylphenobarbital.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Methylphenobarbital.
AmilorideMethylphenobarbital may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Methylphenobarbital.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Methylphenobarbital.
AmisulprideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amitriptyline.
AmlodipineMethylphenobarbital may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amperozide.
AmrinoneThe metabolism of Amrinone can be increased when combined with Methylphenobarbital.
Amyl NitriteMethylphenobarbital may increase the hypotensive activities of Amyl Nitrite.
ApraclonidineMethylphenobarbital may increase the hypotensive activities of Apraclonidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Aripiprazole.
ArmodafinilThe metabolism of Methylphenobarbital can be decreased when combined with Armodafinil.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Methylphenobarbital.
ArticaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Asenapine.
AtenololMethylphenobarbital may increase the hypotensive activities of Atenolol.
AzaperoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Azaperone.
AzelastineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methylphenobarbital.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Methylphenobarbital.
Azilsartan medoxomilMethylphenobarbital may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Methylphenobarbital.
BaclofenThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbital.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Methylphenobarbital.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Methylphenobarbital.
BenazeprilMethylphenobarbital may increase the hypotensive activities of Benazepril.
BendroflumethiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Methylphenobarbital.
BenzocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Methylphenobarbital.
BetaxololMethylphenobarbital may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Methylphenobarbital.
BisoprololMethylphenobarbital may increase the hypotensive activities of Bisoprolol.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Methylphenobarbital.
BortezomibThe metabolism of Methylphenobarbital can be decreased when combined with Bortezomib.
BretyliumMethylphenobarbital may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
BrimonidineMethylphenobarbital may increase the hypotensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brotizolam.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Methylphenobarbital.
BumetanideMethylphenobarbital may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methylphenobarbital.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Methylphenobarbital.
BuprenorphineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methylphenobarbital.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methylphenobarbital.
ButacaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methylphenobarbital.
CanagliflozinMethylphenobarbital may increase the hypotensive activities of Canagliflozin.
CandesartanMethylphenobarbital may increase the hypotensive activities of Candesartan.
CaptoprilMethylphenobarbital may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methylphenobarbital.
CarbinoxamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carisoprodol.
CarteololMethylphenobarbital may increase the hypotensive activities of Carteolol.
CarvedilolMethylphenobarbital may increase the hypotensive activities of Carvedilol.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Methylphenobarbital.
CetirizineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Methylphenobarbital can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methylphenobarbital.
ChlormezanoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chloroprocaine.
ChlorothiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenobarbital.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorprothixene.
ChlorthalidoneMethylphenobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Methylphenobarbital can be decreased when combined with Cholecalciferol.
CilazaprilMethylphenobarbital may increase the hypotensive activities of Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Methylphenobarbital.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Methylphenobarbital.
CimetidineThe metabolism of Methylphenobarbital can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methylphenobarbital.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Methylphenobarbital.
CitalopramThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Citalopram.
CitalopramThe metabolism of Methylphenobarbital can be decreased when combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clemastine.
ClevidipineMethylphenobarbital may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clonazepam.
ClonidineMethylphenobarbital may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Methylphenobarbital.
ClopidogrelThe metabolism of Methylphenobarbital can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methylphenobarbital.
ClotrimazoleThe metabolism of Methylphenobarbital can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenobarbital.
CocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methylphenobarbital.
CrizotinibThe metabolism of Methylphenobarbital can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.
CyproheptadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyproheptadine.
DabrafenibThe serum concentration of Methylphenobarbital can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dantrolene.
DapagliflozinMethylphenobarbital may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenobarbital.
DapoxetineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dapoxetine.
DarodipineThe metabolism of Darodipine can be increased when combined with Methylphenobarbital.
DelavirdineThe metabolism of Methylphenobarbital can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dexbrompheniramine.
DexmedetomidineMethylphenobarbital may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methylphenobarbital.
DextromoramideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methylphenobarbital.
DezocineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methylphenobarbital.
DiclofenamideMethylphenobarbital may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Methylphenobarbital.
DifenoxinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydromorphine.
DiltiazemMethylphenobarbital may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dimenhydrinate.
DinutuximabMethylphenobarbital may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Diphenoxylate.
DipyridamoleMethylphenobarbital may increase the hypotensive activities of Dipyridamole.
DoramectinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Doramectin.
DosulepinThe metabolism of Dosulepin can be increased when combined with Methylphenobarbital.
DotarizineThe metabolism of Dotarizine can be increased when combined with Methylphenobarbital.
DoxazosinMethylphenobarbital may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Doxepin.
DoxorubicinThe metabolism of Methylphenobarbital can be decreased when combined with Doxorubicin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Methylphenobarbital.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
DoxylamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenobarbital.
DrotebanolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methylphenobarbital.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Methylphenobarbital.
EcgonineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Methylphenobarbital.
EmpagliflozinMethylphenobarbital may increase the hypotensive activities of Empagliflozin.
EnalaprilMethylphenobarbital may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methylphenobarbital.
EntacaponeThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Entacapone.
EperisoneThe metabolism of Eperisone can be increased when combined with Methylphenobarbital.
EplerenoneMethylphenobarbital may increase the hypotensive activities of Eplerenone.
EprosartanMethylphenobarbital may increase the hypotensive activities of Eprosartan.
EscitalopramThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Escitalopram.
Eslicarbazepine acetateThe metabolism of Methylphenobarbital can be decreased when combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Methylphenobarbital.
EsmololMethylphenobarbital may increase the hypotensive activities of Esmolol.
EsomeprazoleThe metabolism of Methylphenobarbital can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methylphenobarbital.
Etacrynic acidMethylphenobarbital may increase the hypotensive activities of Etacrynic acid.
EthanolMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methylphenobarbital.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylphenobarbital.
EthosuximideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Methylphenobarbital.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylphenobarbital.
EtoperidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etorphine.
EtravirineThe metabolism of Methylphenobarbital can be decreased when combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ezogabine.
FelbamateThe serum concentration of Methylphenobarbital can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Felbamate.
FelodipineMethylphenobarbital may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fencamfamine.
FendilineThe metabolism of Fendiline can be increased when combined with Methylphenobarbital.
FenfluramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methylphenobarbital.
FexofenadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flibanserin.
FluconazoleThe metabolism of Methylphenobarbital can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Methylphenobarbital.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methylphenobarbital.
FlunitrazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluoxetine.
FluoxetineThe metabolism of Methylphenobarbital can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenobarbital.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methylphenobarbital.
FluspirileneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluvoxamine.
FosinoprilMethylphenobarbital may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fospropofol.
FurosemideMethylphenobarbital may increase the hypotensive activities of Furosemide.
GabapentinThe metabolism of Gabapentin can be increased when combined with Methylphenobarbital.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methylphenobarbital.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Methylphenobarbital can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Glutethimide.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Methylphenobarbital.
GuanfacineMethylphenobarbital may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methylphenobarbital.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methylphenobarbital.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenobarbital.
HalothaneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hexobarbital.
HydralazineMethylphenobarbital may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hydrocodone.
HydroflumethiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylphenobarbital.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
HydroxyzineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Indalpine.
IndapamideMethylphenobarbital may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Methylphenobarbital.
IndinavirThe metabolism of Methylphenobarbital can be decreased when combined with Indinavir.
IrbesartanMethylphenobarbital may increase the hypotensive activities of Irbesartan.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methylphenobarbital.
IsoniazidThe metabolism of Methylphenobarbital can be decreased when combined with Isoniazid.
Isosorbide DinitrateMethylphenobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateMethylphenobarbital may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprineMethylphenobarbital may increase the hypotensive activities of Isoxsuprine.
IsradipineMethylphenobarbital may increase the hypotensive activities of Isradipine.
KetamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketobemidone.
KetoconazoleThe metabolism of Methylphenobarbital can be decreased when combined with Ketoconazole.
LabetalolMethylphenobarbital may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Methylphenobarbital.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Methylphenobarbital.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methylphenobarbital.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Methylphenobarbital.
LevetiracetamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levetiracetam.
LevobunololMethylphenobarbital may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methylphenobarbital.
LisinoprilMethylphenobarbital may increase the hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lofentanil.
LopinavirThe metabolism of Methylphenobarbital can be increased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methylphenobarbital.
LosartanMethylphenobarbital may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenobarbital.
Lu AA21004The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lu AA21004.
LuliconazoleThe serum concentration of Methylphenobarbital can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Methylphenobarbital can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Methylphenobarbital.
ManidipineThe metabolism of Manidipine can be increased when combined with Methylphenobarbital.
MannitolMethylphenobarbital may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Maprotiline.
MecamylamineMethylphenobarbital may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Medetomidine.
MefloquineThe therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methylphenobarbital.
MesoridazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methylphenobarbital.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methaqualone.
MethazolamideMethylphenobarbital may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methylphenobarbital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methsuximide.
MethyclothiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaMethylphenobarbital may increase the hypotensive activities of Methyldopa.
MetipranololMethylphenobarbital may increase the hypotensive activities of Metipranolol.
MetolazoneMethylphenobarbital may increase the orthostatic hypotensive activities of Metolazone.
MetoprololMethylphenobarbital may increase the hypotensive activities of Metoprolol.
MetyrosineMethylphenobarbital may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
MibefradilThe metabolism of Mibefradil can be increased when combined with Methylphenobarbital.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methylphenobarbital.
MilnacipranThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
MinoxidilMethylphenobarbital may increase the hypotensive activities of Minoxidil.
MirtazapineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methylphenobarbital.
MoclobemideThe metabolism of Methylphenobarbital can be decreased when combined with Moclobemide.
ModafinilThe metabolism of Methylphenobarbital can be decreased when combined with Modafinil.
MoexiprilMethylphenobarbital may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methylphenobarbital.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
NabiloneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nabilone.
NadololMethylphenobarbital may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methylphenobarbital.
NebivololMethylphenobarbital may increase the hypotensive activities of Nebivolol.
NelfinavirThe metabolism of Methylphenobarbital can be decreased when combined with Nelfinavir.
NesiritideMethylphenobarbital may increase the hypotensive activities of Nesiritide.
NevirapineThe metabolism of Methylphenobarbital can be increased when combined with Nevirapine.
NicardipineMethylphenobarbital may increase the hypotensive activities of Nicardipine.
NicardipineThe metabolism of Methylphenobarbital can be decreased when combined with Nicardipine.
NifedipineMethylphenobarbital may increase the hypotensive activities of Nifedipine.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Methylphenobarbital.
NiludipineThe metabolism of Niludipine can be increased when combined with Methylphenobarbital.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Methylphenobarbital.
NimesulideThe metabolism of Nimesulide can be increased when combined with Methylphenobarbital.
NimodipineMethylphenobarbital may increase the hypotensive activities of Nimodipine.
NisoldipineMethylphenobarbital may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Methylphenobarbital.
NitroglycerinMethylphenobarbital may increase the hypotensive activities of Nitroglycerin.
NitroprussideMethylphenobarbital may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Olanzapine.
OlmesartanMethylphenobarbital may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Olopatadine.
OmeprazoleThe metabolism of Methylphenobarbital can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Opium.
OrlistatThe serum concentration of Methylphenobarbital can be decreased when it is combined with Orlistat.
OrphenadrineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methylphenobarbital.
OsanetantThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methylphenobarbital.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Methylphenobarbital.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methylphenobarbital.
OxybuprocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methylphenobarbital.
OxymorphoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Paliperidone.
PantoprazoleThe metabolism of Methylphenobarbital can be decreased when combined with Pantoprazole.
PapaverineMethylphenobarbital may increase the hypotensive activities of Papaverine.
ParaldehydeMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Methylphenobarbital.
ParoxetineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Paroxetine.
ParoxetineThe metabolism of Methylphenobarbital can be decreased when combined with Paroxetine.
PenbutololMethylphenobarbital may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methylphenobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methylphenobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perampanel.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Methylphenobarbital.
PerindoprilMethylphenobarbital may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perphenazine.
PethidineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methylphenobarbital.
PhenindioneThe metabolism of Phenindione can be increased when combined with Methylphenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Methylphenobarbital.
PhenytoinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pimozide.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Methylphenobarbital.
PindololMethylphenobarbital may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pizotifen.
PolythiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pomalidomide.
PractololThe serum concentration of Practolol can be decreased when it is combined with Methylphenobarbital.
PramipexoleMethylphenobarbital may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Prazepam.
PrazosinMethylphenobarbital may increase the hypotensive activities of Prazosin.
PregabalinThe metabolism of Pregabalin can be increased when combined with Methylphenobarbital.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methylphenobarbital.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Methylphenobarbital.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methylphenobarbital.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Methylphenobarbital.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methylphenobarbital.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenobarbital.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenobarbital.
PromethazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Methylphenobarbital.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methylphenobarbital.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methylphenobarbital.
PropoxycaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Propoxycaine.
PropranololMethylphenobarbital may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with PSD502.
PyridoxineThe metabolism of Methylphenobarbital can be increased when combined with Pyridoxine.
QuazepamThe serum concentration of Methylphenobarbital can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Quazepam.
QuetiapineMethylphenobarbital may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenobarbital.
QuinaprilMethylphenobarbital may increase the hypotensive activities of Quinapril.
QuinethazoneMethylphenobarbital may increase the orthostatic hypotensive activities of Quinethazone.
RamelteonThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ramelteon.
RamiprilMethylphenobarbital may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenobarbital.
ReserpineMethylphenobarbital may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylphenobarbital.
RifampicinThe metabolism of Methylphenobarbital can be increased when combined with Rifampicin.
RiociguatMethylphenobarbital may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Methylphenobarbital.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenobarbital.
RomifidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Romifidine.
RopiniroleMethylphenobarbital may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methylphenobarbital.
RotigotineMethylphenobarbital may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methylphenobarbital.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methylphenobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sertraline.
SertralineThe metabolism of Methylphenobarbital can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sodium oxybate.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Methylphenobarbital.
SorafenibThe metabolism of Methylphenobarbital can be decreased when combined with Sorafenib.
SotalolMethylphenobarbital may increase the hypotensive activities of Sotalol.
SpironolactoneMethylphenobarbital may increase the hypotensive activities of Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methylphenobarbital.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenobarbital.
SuvorexantThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tasimelteon.
TelmisartanMethylphenobarbital may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methylphenobarbital.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Methylphenobarbital.
TerazosinMethylphenobarbital may increase the hypotensive activities of Terazosin.
TetrabenazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetrodotoxin.
ThalidomideMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methylphenobarbital.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Methylphenobarbital.
ThiamylalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methylphenobarbital.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenobarbital.
ThiotepaThe metabolism of Methylphenobarbital can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Methylphenobarbital.
TiclopidineThe metabolism of Methylphenobarbital can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tiletamine.
TimololMethylphenobarbital may increase the hypotensive activities of Timolol.
TizanidineMethylphenobarbital may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methylphenobarbital.
TolcaponeThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Methylphenobarbital.
TopiramateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Topiramate.
TorasemideMethylphenobarbital may increase the hypotensive activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methylphenobarbital.
TrandolaprilMethylphenobarbital may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Methylphenobarbital.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methylphenobarbital.
TrazodoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Trazodone.
TriamtereneMethylphenobarbital may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Triazolam.
TrichlormethiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenobarbital.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenobarbital.
TrimipramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Methylphenobarbital.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methylphenobarbital.
ValsartanMethylphenobarbital may increase the hypotensive activities of Valsartan.
VenlafaxineThe metabolism of Methylphenobarbital can be decreased when combined with Venlafaxine.
VerapamilMethylphenobarbital may increase the hypotensive activities of Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vilazodone.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Methylphenobarbital.
VoriconazoleThe metabolism of Methylphenobarbital can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Methylphenobarbital.
XylazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Methylphenobarbital.
ZaleplonThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zaleplon.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Methylphenobarbital.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Methylphenobarbital.
ZimelidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenobarbital.
ZolazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methylphenobarbital.
ZonisamideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  7. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  8. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
  9. Roden WH, Peugh LD, Jansen LA: Altered GABA(A) receptor subunit expression and pharmacology in human Angelman syndrome cortex. Neurosci Lett. 2010 Oct 15;483(3):167-72. doi: 10.1016/j.neulet.2010.08.001. Epub 2010 Aug 6. [PubMed:20692323 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  3. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23